Compare Stocks

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRA Biofrontera	$2.60	$2.95	$2.09 ▼ $7.54	$73.73M	1.02	27,512 shs	7,263 shs
CYAD Celyad Oncology	$0.60	$0.67	$0.46 ▼ $3.07	$15.91M	N/A	N/A	3,009 shs
EVLO Evelo Biosciences	$0.05	$0.05	$0.03 ▼ $13.93	$940K	2.03	40,657 shs	31,190 shs
NERV Minerva Neurosciences	$2.44 +0.4%	$3.23	$2.29 ▼ $13.49	$17.03M	0.21	99,925 shs	4,157 shs
OBSV ObsEva	$0.01	$0.02	$0.08 ▼ $2.14	$390K	0.68	8.94 million shs	50,231 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRA Biofrontera	0.00%	0.00%	0.00%	0.00%	0.00%
CYAD Celyad Oncology	0.00%	0.00%	0.00%	0.00%	-12.73%
EVLO Evelo Biosciences	+3.39%	-8.60%	-8.60%	-29.69%	-97.72%
NERV Minerva Neurosciences	-2.78%	-2.39%	-4.67%	-69.90%	-5.77%
OBSV ObsEva	-60.00%	-60.00%	-75.00%	-96.00%	-97.62%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	3.6126 of 5 stars	3.0	5.0	0.0	4.6	1.8	0.0	0.0
OBSV ObsEva	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRA Biofrontera	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A
EVLO Evelo Biosciences	2.00	Hold	N/A	N/A
NERV Minerva Neurosciences	2.00	Hold	$11.00	351.47% Upside
OBSV ObsEva	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest NERV, EVLO, OBSV, CYAD, and BFRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/27/2024	NERV Minerva Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$11.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRA Biofrontera	$36.19M	2.04	N/A	N/A	$0.35 per share	7.43
CYAD Celyad Oncology	$110K	144.65	N/A	N/A	$0.20 per share	3.00
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	($0.92) per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.07) per share	N/A
OBSV ObsEva	$20.11M	0.02	N/A	N/A	$0.41 per share	0.01

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRA Biofrontera	-$14.88M	-$0.73	N/A	∞	N/A	-59.44%	-93.31%	-24.02%	N/A
CYAD Celyad Oncology	-$9.14M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EVLO Evelo Biosciences	-$114.53M	-$13.29	N/A	∞	N/A	N/A	N/A	-189.58%	5/13/2024 (Estimated)
NERV Minerva Neurosciences	-$30M	-$4.65	N/A	N/A	N/A	N/A	N/A	-50.27%	5/20/2024 (Estimated)
OBSV ObsEva	-$58.38M	-$0.92	N/A	∞	N/A	N/A	-416.36%	-92.01%	N/A

Latest NERV, EVLO, OBSV, CYAD, and BFRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/22/2024	Q4 2023	NERV Minerva Neurosciences	-$0.88	-$1.19	-$0.31	-$1.19	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
OBSV ObsEva	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRA Biofrontera	0.13	1.26	1.13
CYAD Celyad Oncology	N/A	N/A	N/A
EVLO Evelo Biosciences	N/A	0.48	0.48
NERV Minerva Neurosciences	N/A	12.57	12.58
OBSV ObsEva	N/A	0.61	0.61

Ownership

Institutional Ownership

Company	Institutional Ownership
BFRA Biofrontera	60.07%
CYAD Celyad Oncology	N/A
EVLO Evelo Biosciences	0.31%
NERV Minerva Neurosciences	34.56%
OBSV ObsEva	17.52%

Insider Ownership

Company	Insider Ownership
BFRA Biofrontera	N/A
CYAD Celyad Oncology	0.94%
EVLO Evelo Biosciences	1.02%
NERV Minerva Neurosciences	6.40%
OBSV ObsEva	14.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRA Biofrontera	138	28.36 million	N/A	Not Optionable
CYAD Celyad Oncology	95	26.52 million	26.28 million	Not Optionable
EVLO Evelo Biosciences	66	18.98 million	18.79 million	No Data
NERV Minerva Neurosciences	9	6.99 million	6.55 million	Not Optionable
OBSV ObsEva	48	77.97 million	66.74 million	Not Optionable

NERV, EVLO, OBSV, CYAD, and BFRA Headlines

Source	Headline
	StockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV) americanbankingnews.com - April 20 at 2:22 AM
	ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin globenewswire.com - April 3 at 1:00 AM
	ObsEva Announces Update on Board of Directors globenewswire.com - March 19 at 2:00 AM
	ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023 globenewswire.com - February 28 at 1:00 AM
	ObsEva Stock (OTC:OBSEF) Dividends: History, Yield and Dates benzinga.com - February 26 at 12:34 AM
	ObsEva SA OBSN morningstar.com - November 11 at 10:37 PM
	ObsEva SA OBSEF morningstar.com - November 11 at 7:36 AM
	ObsEva (NASDAQ: OBSV) fool.com - June 18 at 11:34 PM
	Tocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserver news.google.com - May 10 at 1:37 AM
	ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Finance news.google.com - May 2 at 1:32 PM
	ObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaq news.google.com - May 2 at 8:31 AM
	ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswire news.google.com - May 2 at 1:20 AM
	Gameto Appoints Teri Loxam as Chief Financial Officer - citybiz news.google.com - April 28 at 11:20 PM
	ObsEva Annual Report 2022 - Marketscreener.com news.google.com - April 28 at 6:20 PM
	ObsEva Annual Report 2022 - Yahoo Finance news.google.com - April 28 at 6:20 PM
	ObsEva Annual Report 2022 - Benzinga news.google.com - April 28 at 1:20 PM
	ObsEva Annual Report 2022 - EIN News news.google.com - April 28 at 1:20 PM
	Gameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswire news.google.com - April 28 at 8:19 AM
	Endometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journal news.google.com - April 26 at 6:27 PM
	Endometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPR news.google.com - April 23 at 8:45 PM
	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.com news.google.com - April 21 at 3:44 PM
	ObsEva Announces Change of Central Securities Depositary - Yahoo Finance news.google.com - April 20 at 11:41 PM
	ObsEva Announces Change of Central Securities Depositary - GlobeNewswire news.google.com - April 20 at 1:10 AM
	Tackling Reproductive Health and Fertility Care - Pharmaceutical Executive news.google.com - April 13 at 6:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Biofrontera

NASDAQ:BFRA

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Celyad Oncology

NASDAQ:CYAD

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Evelo Biosciences

NASDAQ:EVLO

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Minerva Neurosciences

NASDAQ:NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

ObsEva

NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial